Clinical Trial Detail

NCT ID NCT01582672
Title Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Argos Therapeutics
Indications

renal cell carcinoma

Therapies

Sunitinib

Age Groups: adult

No variant requirements are available.